Extended-release oral ketamine tablet KET01 enters late-stage trials for at-home depression treatment
By
Liz Scherer
Summary
An extended-release oral ketamine tablet (KET01) is in late-stage development as a potential at-home treatment for treatment-resistant depression (TRD). While ketamine and esketamine have offered rapid relief for TRD patients, they require supervised administration due to risks like dissociation, cardiovascular issues, and abuse potential. The new formulation aims to address these constraints by providing a take-home option, though questions remain about whether removing the supervised clinical experience might blunt ketamine's therapeutic value.
Source
Twitter / XExtended-release oral ketamine tablet KET01 enters late-stage trials for at-home depression treatmentmdsc.peKey quotes
· 3 pulledFor patients with treatment-resistant depression (TRD), ketamine and esketamine have offered something that conventional antidepressants often cannot: relief that can arrive quickly.
But that speed has come with practical and clinical constraints — dissociation, cardiovascular risks, abuse concerns, and the need for supervised administration.
KET01, a prolonged-release ketamine hydrochloride formulation, is being studied as an add-on treatment that could potentially be taken at home.
You might also wanna read
Study identifies mu-opioid receptors in prefrontal interneurons as key to ketamine's rapid antidepressant effects
This study investigates the molecular mechanisms behind ketamine's rapid antidepressant effects, identifying that its behavioral effects dep
Pharmaceutical LSD (MM120) Shows Promise in Treating Generalized Anxiety Disorder in UCSF Clinical Trials
Researchers at UCSF are testing MM120, a pharmaceutical form of LSD, as a treatment for generalized anxiety disorder (GAD). The treatment ha
Synthetic Psilocybin Shows Strong Results in Treatment-Resistant Depression Trials
Compass Pathways, a British biotech company, announced strong results from two late-stage trials showing that a synthetic form of psilocybin
economist.com·4mo ago
Exploring the Role of NMDA Receptor Antagonists in Anesthesia, Alzheimer's, and Depression
The article delves into the functions and effects of NMDA Receptor Antagonists, highlighting their potential uses in anesthesia, Alzheimer's
grillbert.substack.com·11mo ago
Systematic Review Ranks Efficacy and Acceptability of Antipsychotics for Major Depressive Disorder
This systematic review and network meta-analysis compares FDA-approved atypical antipsychotics used as adjunctive treatment for major depres
doi.org·19d ago
FDA Initiates Approval of Leucovorin Calcium for Cerebral Folate Deficiency
The FDA has initiated the approval of leucovorin calcium tablets for patients with cerebral folate deficiency (CFD), a neurological conditio
fda.gov·9mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.